


ACUSON Juniper ultrasound system

You've got the power to fight the liver disease epidemic

Release 3.0

siemens-healthineers.com/juniper



The growing challenge of liver disease

Liver disease is a silent epidemic, nearly 30% of the global population is affected by it, while less than 5% of them are aware of their condition.¹

In its most common form, MASLD*, can silently evolve into MASH**, and later into advanced fibrosis, cirrhosis, or liver cancer. People with obesity or type 2 diabetes face two to three times higher risk of reaching these advanced stages.²

This path can change. When detected early, liver disease can often be treated — or even reversed. Ultrasound makes this possible by offering an accessible, affordable, and safe way to detect disease before it progresses.

*MASLD: Metabolic dysfunction–associated steatotic liver disease. Formerly known as non-alcoholic fatty liver disease (NAFLD).

**MASH: Metabolic dysfunction–associated steatohepatitis.

30%

of the global population is affected by MASLD

< 5%

are aware of their condition


20–30%

of MASLD cases progress to MASH

2–3x

higher risk of liver disease for people with obesity or type 2 diabetes

Liver disease is reversible if caught early enough



Ultrasound to break the silence of an epidemic — at scale

Current barriers to early detection of liver disease

- Early stages are silent, leading to delayed diagnosis
- Liver fat and fibrosis aren't routinely screened, especially in primary care
- Limited access to gold-standard diagnostics, like MRI and invasive biopsy, due to cost and availability
- Low awareness among patients and clinicians about MASLD and its risks

The solution: ACUSON Juniper ultrasound system

- Enables early detection and routine monitoring
- Non-invasive, accessible and scalable
- Suitable for population-level MASLD screening
- Delivers MRI-comparable accuracy at a fraction of the cost
- Enhances clinical equity across healthcare settings

Power of acting early

Proactive care starts with early detection.


With ACUSON Juniper, you can make fast, non-invasive assessments in just one minute.³ Integrated UDFF and pSWE technologies give you reliable, actionable insights to identify and monitor liver disease early – enabling proactive, efficient care for every patient.

Power of access

ACUSON Juniper makes liver screening and disease management possible for everyone, everywhere.

Clinicians can detect steatosis and assess its progression — non-invasively, at low cost, and at scale.

Ultrasound unlocks the potential to reverse liver disease and improve global health.



Power of clinically validated tools

Clinically validated ultrasound solutions give healthcare providers the confidence to see more, act sooner, and deliver better outcomes.

ACUSON Juniper delivers consistency and confidence in every result with a portfolio of imaging tools for liver care:

Ultrasound-derived fat fraction (UDFF)

Quantifies hepatic fat in good agreement with MRI-PDF for MASLD screening

pSWE

Quantifies liver stiffness to assess chronic liver disease

Contrast-enhanced ultrasound (CEUS)

For enhanced lesion characterization

Needle visualization

Safe, precise targeting during liver biopsies and interventions

Single crystal transducers

Improved penetration with high resolution (e.g. 6C1)


Auto TEQ

Auto-adjusts imaging parameters for consistent results


Compact and mobile

Ideal for bedside liver monitoring and transplant follow-up


ACUSON Juniper liver care portfolio




UDFF delivers reproducible, reliable and detailed liver assessment data to quickly quantify liver steatosis.



pSWE provides measurements of liver tissue stiffness and can aid in monitoring chronic liver disease.



Contrast-enhanced ultrasound (CEUS) is demonstrated on the 6C1 for the characterization of focal liver lesions.



Needle visualization enhances safety and precision during liver biopsies through a proprietary algorithm that improves needle display and operator confidence.



Integrated Auto Flash Color Artifact Suppression technology, delivers precise, optimized color with no user interaction.



Single crystal transducers deliver high-resolution, uniform images with sharp borders for confident liver assessments.

It's time to act

It's time to focus on early detection – the only way to identify, and even reverse, liver disease before it advances to MASH, advanced fibrosis, cirrhosis, or liver cancer.

It's time to make liver scanning as common as lungs, heart, and breast imaging – because it's ultrasound that can break the silence of this epidemic and change billions of lives for the better.

It's time to make the invisible unmissable.

ACUSON Juniper. You've got the power.

Siemens Healthineers Headquarters
Siemens Healthineers AG
Siemensstr. 3
91301 Forchheim, Germany
Phone: +49 9191 18-0
siemens-healthineers.com

Legal Manufacturer
Siemens Medical Solutions USA, Inc.
Ultrasound
22010 S.E. 51st Street
Issaquah, WA 98029, USA
Phone: 1-888-826-9702
siemens-healthineers.com/ultrasound

Endnotes

¹ Yip TC-F, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL-H, Adams LA, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. *Hepatology [Internet]*. 2023;77(4):1404–27. Available from: <http://dx.doi.org/10.1002/hep.32774>

² Gastaldelli A, Cusi K. From MASH to diabetes and from diabetes to MASH: Mechanisms and treatment options. *JHEP Rep [Internet]*. 2019;1(4):312–28. Available from: <http://dx.doi.org/10.1016/j.jhepr.2019.07.002>

³ Data on file

The products/features mentioned in this document may not be commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details. Standalone clinical images may have been cropped to better visualize pathology.